Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

T. Kalincik, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. ButlerM. Slee, A. Kermode, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueven, MSBase Study Grp

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)596-597
Number of pages2
JournalMultiple Sclerosis
Volume23
Publication statusPublished - Oct 2017
Event7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) - Paris, France
Duration: 25 Oct 201728 Oct 2017

Cite this

Kalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Solaro, C., Grand'Maison, F., Hupperts, R., Prevost, J., Sola, P., Ferraro, D., Terzi, M., ... MSBase Study Grp (2017). Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. Multiple Sclerosis, 23, 596-597.